John S. Stafford III Acquires 38,300 Shares of Xencor Inc (XNCR) Stock
Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III bought 38,300 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $29.02 per share, with a total value of $1,111,466.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Xencor stock traded down $0.15 during mid-day trading on Tuesday, hitting $30.27. 96,145 shares of the company were exchanged, compared to its average volume of 218,691. Xencor Inc has a 1-year low of $27.57 and a 1-year high of $48.38. The firm has a market capitalization of $1.69 billion, a P/E ratio of -23.11 and a beta of 1.40.
A number of research analysts recently commented on XNCR shares. Raymond James started coverage on Xencor in a research note on Thursday, March 14th. They issued an “outperform” rating and a $27.85 target price for the company. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Saturday, December 1st. BidaskClub lowered Xencor from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Nomura lowered Xencor from a “neutral” rating to a “reduce” rating and dropped their price objective for the stock from $28.00 to $21.00 in a research note on Friday, February 22nd. Finally, Piper Jaffray Companies increased their price objective on Xencor to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Two analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. Xencor currently has a consensus rating of “Buy” and an average price target of $40.43.
ILLEGAL ACTIVITY WARNING: “John S. Stafford III Acquires 38,300 Shares of Xencor Inc (XNCR) Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/john-s-stafford-iii-acquires-38300-shares-of-xencor-inc-xncr-stock/2902518.html.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Article: The Structure of a Futures Contract
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.